Is Meloxicam Appropriate First-Line Treatment for Lower Back Pain?
Yes, meloxicam is an appropriate first-line treatment for acute uncomplicated lower back pain in adults without NSAID contraindications, as NSAIDs (including meloxicam) are consistently recommended as first-line pharmacologic therapy by major clinical practice guidelines.
Guideline-Based Recommendation
The 2017 American College of Physicians clinical practice guideline establishes NSAIDs as first-line pharmacologic therapy for acute low back pain 1, 2. This recommendation is supported by:
- Moderate-quality evidence showing NSAIDs provide small improvement in pain intensity compared to placebo (mean difference -7.29 points on 0-100 VAS scale) 1
- High-quality evidence demonstrating small improvement in disability (mean difference -2.02 on RMDQ 0-24 scale) 2
- Low-quality evidence showing greater likelihood of global improvement (RR 1.40) 2
The 2020 Cochrane systematic review confirms these findings with high to moderate certainty evidence, though noting the magnitude of effects is small and possibly not clinically relevant 3.
Why Meloxicam Specifically?
Meloxicam is a preferential COX-2 inhibitor NSAID with several advantages:
- Class equivalence: Moderate-quality evidence shows no meaningful differences between individual NSAIDs for acute low back pain 1, 2
- Safety profile: As a preferential COX-2 inhibitor, meloxicam theoretically offers better GI tolerability than non-selective NSAIDs, though evidence shows no clear difference in adverse events between COX-2 selective and non-selective NSAIDs 2
- Clinical effectiveness: Observational data shows 75.2% of patients achieved complete pain relief with meloxicam 15 mg/day within mean 8.6 days 4
Practical Implementation
Dosing: Start meloxicam 15 mg daily (oral or intramuscular for first 3-5 days if severe pain, then transition to oral) 4, 5
Expected outcomes:
- Pain reduction begins within 24 hours
- Maximum benefit typically achieved within 1-2 weeks
- Short-term use only (effects are primarily short-term per guidelines) 1
Important Caveats
Acetaminophen is NOT recommended: New evidence demonstrates acetaminophen is ineffective for acute low back pain, contradicting older recommendations 1, 2. Do not use acetaminophen as first-line therapy.
Predictors of better response to meloxicam 4:
- Age <65 years
- First episode of low back pain
- History of good response to NSAIDs previously
Predictors of poorer response 4:
- Severe baseline pain (NRS ≥7)
- Pain at rest or night
- Radicular symptoms (sciatica)
For patients with these poor prognostic features, consider adding skeletal muscle relaxants early, though evidence for combination therapy is inconsistent 2.
Adverse events: Very low quality evidence shows no clear difference in adverse events between NSAIDs and placebo in short-term use (RR 0.86) 2. However, standard NSAID precautions apply: avoid in patients with GI bleeding history, cardiovascular disease, renal insufficiency, or pregnancy 4.
Alternative if NSAIDs Fail or Contraindicated
If meloxicam/NSAIDs are ineffective after 3-5 days or contraindicated:
- Skeletal muscle relaxants (moderate evidence for short-term pain relief but cause sedation) 1, 2
- NOT opioids for acute low back pain (insufficient evidence) 2
- NOT benzodiazepines (ineffective per recent evidence) 1
The systematic review of guidelines confirms NSAIDs are the most consistently recommended first-line pharmacological therapy across all major international guidelines 6.